Current Gastroenterology Reports

, Volume 8, Issue 6, pp 467–469

Clinical trials report

  • Stephen B. Hanauer


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Targan SR, Karp LC: Defects in mucosal immunity leading to ulcerative colitis. Immunol Rev 2005, 206:296–305.PubMedCrossRefGoogle Scholar
  2. 2.
    Bamias G, Nyce MR, De La Rue SA, Cominelli F: New concepts in the pathophysiology of inflammatory bowel disease. Ann Intern Med 2005, 143:895–904.PubMedGoogle Scholar
  3. 3.
    Gornet JM, Couve S, Hassani Z, et al.: Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. Aliment Pharmacol Ther 2003, 18:175–181.PubMedCrossRefGoogle Scholar
  4. 4.
    Su C, Salzberg BA, Lewis JD, et al.: Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002, 97:2577–2584.PubMedCrossRefGoogle Scholar
  5. 5.
    Chey WY, Hussain A, Ryan C, et al.: Infliximab for refractory ulcerative colitis. Am J Gastroenterol 2001, 96:2373–2381.PubMedCrossRefGoogle Scholar
  6. 6.
    Jarnerot G, Hertervig E, Friis-Liby I, et al.: Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005, 128:1805–1811.PubMedCrossRefGoogle Scholar
  7. 7.
    Probert CS, Hearing SD, Schreiber S, et al.: Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003, 52:998–1002.PubMedCrossRefGoogle Scholar
  8. 8.
    Lichtenstein GR, Abreu MT, Cohen R, Tremaine W: American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006, 130:935–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Sandborn WJ, Yednock TA: Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. Am J Gastroenterol 2003, 98:2372–2382.PubMedCrossRefGoogle Scholar
  10. 10.
    Van AsscheG, Van Ranst M, Sciot R, et al.: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 2005, 353:362–368.PubMedCrossRefGoogle Scholar
  11. 11.
    Kleinschmidt-DeMasters BK, Tyler KL: Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005, 353:369–374.PubMedCrossRefGoogle Scholar
  12. 12.
    Drazen JM: Patients at risk. N Engl J Med 2005, 353:417.PubMedCrossRefGoogle Scholar
  13. 13.
    Berger JR, Koralnik IJ: Progressive multifocal leukoencephalopathy and natalizumab—unforeseen consequences. N Engl J Med 2005, 353:414–416.PubMedCrossRefGoogle Scholar
  14. 14.
    Adelman B, Sandrock A, Panzara MA: Natalizumab and progressive multifocal leukoencephalopathy. N Engl J Med 2005, 353:432–433.PubMedCrossRefGoogle Scholar
  15. 15.
    Ghosh S, Goldin E, Gordon FH, et al.: Natalizumab for active Crohn’s disease. N Engl J Med 2003, 348:24–32.PubMedCrossRefGoogle Scholar
  16. 16.
    Targan SR, Feagan B, Fedorak R, et al.: Natalizumab induces sustained response and remission in patients with active Crohn’s disease: Results from the Encore trial. Distinguished Abstract Plenary. Gastroenterology 2006, 130:A-108Google Scholar
  17. 17.
    Feagan BG, Greenberg GR, Wild G, et al.: Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005, 352:2499–2507.PubMedCrossRefGoogle Scholar
  18. 18.
    Sandborn W, Targan S: A safety evaluation for progressive multifocal leukoencephalopathy (PML) in greater than 3,500 patients with Crohn’s disease (CD), multiple sclerosis (MS) and rheumatoid arthritis (RA) previously treated with natalizumab in clinical trials [abstract]. Gastroenterology 2006, 130(4)S2 #492:A-72.Google Scholar

Copyright information

© Current Science Inc. 2006

Authors and Affiliations

  • Stephen B. Hanauer

There are no affiliations available

Personalised recommendations